{"id":"W2480832378","doi":"10.17925/ee.2014.10.02.98","title":"The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?","year":2014,"lang":"en","type":"editorial","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Glucagon-like peptide 1 receptor; Glucagon-like peptide-1; Insulin; Type 2 diabetes; Receptor; Diabetes mellitus; Agonist; Endocrinology; Pharmacology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004316103,0.0004433616,0.001654085,0.0003483068,0.00003748903,0.0000115221,0.0003931347,0.0003184836,0.0001272112],"category_scores_gemma":[0.0002557155,0.0002754298,0.000157816,0.0004347223,0.0003107564,0.00005502394,0.000136159,0.0006011341,0.00004000454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001556477,"about_ca_system_score_gemma":0.0001730928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000530876,"about_ca_topic_score_gemma":0.0003453527,"domain_scores_codex":[0.9972666,0.0002981696,0.0009892975,0.0004709926,0.0004421779,0.000532755],"domain_scores_gemma":[0.9974898,0.0006285788,0.0007618707,0.0007883633,0.0002870428,0.0000443462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00055358,0.0005783511,0.007727687,0.002496866,0.0005439942,0.00002072926,0.0006813848,0.000001023634,0.00005287174,0.0006667319,0.8133815,0.1732953],"study_design_scores_gemma":[0.003288157,0.001994294,0.001278696,0.001523747,0.0002539762,0.000001008972,0.0002274348,0.000004068761,0.0002752296,0.0001324394,0.9908065,0.0002144462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"review","genre_scores_codex":[0.1186541,0.3437665,0.000004566986,0.006165212,0.5196862,0.006133361,0.0001082168,0.00007994154,0.00540192],"genre_scores_gemma":[0.04046332,0.8463134,0.001166347,0.0008290108,0.1004914,0.001071032,0.00136219,0.000208388,0.008094992],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.5025468,"threshold_uncertainty_score":0.9999698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00987615569664187,"score_gpt":0.2814787907792313,"score_spread":0.2716026350825895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}